Yu J
Biomed J. 2019; 42(2):80-83.
PMID: 31130251
PMC: 6541884.
DOI: 10.1016/j.bj.2019.03.004.
Tao X, Lu Y, Qiu S, Wang Y, Qin J, Fan Z
Cancer Lett. 2017; 408:33-42.
PMID: 28823958
PMC: 5628150.
DOI: 10.1016/j.canlet.2017.08.012.
Scharaw S, Iskar M, Ori A, Boncompain G, Laketa V, Poser I
J Cell Biol. 2016; 215(4):543-558.
PMID: 27872256
PMC: 5119934.
DOI: 10.1083/jcb.201601090.
Maramotti S, Paci M, Manzotti G, Rapicetta C, Gugnoni M, Galeone C
Int J Mol Sci. 2016; 17(4).
PMID: 27104520
PMC: 4849047.
DOI: 10.3390/ijms17040593.
Schmohl J, Todhunter D, Oh S, Vallera D
Toxins (Basel). 2015; 7(10):4067-82.
PMID: 26473923
PMC: 4626721.
DOI: 10.3390/toxins7104067.
Model-based assessment of erlotinib effect in vitro measured by real-time cell analysis.
Benay S, Meille C, Kustermann S, Walter I, Walz A, Gonsard P
J Pharmacokinet Pharmacodyn. 2015; 42(3):275-85.
PMID: 25822652
DOI: 10.1007/s10928-015-9415-3.
The genesis of tyrosine phosphorylation.
Hunter T
Cold Spring Harb Perspect Biol. 2014; 6(5):a020644.
PMID: 24789824
PMC: 3996475.
DOI: 10.1101/cshperspect.a020644.
Changing the receptor specificity of anthrax toxin.
Mechaly A, McCluskey A, Collier R
mBio. 2012; 3(3).
PMID: 22550037
PMC: 3569862.
DOI: 10.1128/mBio.00088-12.
Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling.
Krippendorff B, Oyarzun D, Huisinga W
J Pharmacokinet Pharmacodyn. 2012; 39(2):125-39.
PMID: 22399130
PMC: 3333800.
DOI: 10.1007/s10928-012-9243-7.
A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model.
Oh S, Todhunter D, Panoskaltsis-Mortari A, Buchsbaum D, Toma S, Vallera D
Pancreas. 2012; 41(5):789-96.
PMID: 22258068
PMC: 3336038.
DOI: 10.1097/MPA.0b013e31823b5f2e.
Molecular biology of lung cancer: clinical implications.
Larsen J, Minna J
Clin Chest Med. 2011; 32(4):703-40.
PMID: 22054881
PMC: 3367865.
DOI: 10.1016/j.ccm.2011.08.003.
Molecular imaging with SERS-active nanoparticles.
Zhang Y, Hong H, Myklejord D, Cai W
Small. 2011; 7(23):3261-9.
PMID: 21932216
PMC: 3228876.
DOI: 10.1002/smll.201100597.
The challenge of developing robust drugs to overcome resistance.
Anderson A, Pollastri M, Schiffer C, Peet N
Drug Discov Today. 2011; 16(17-18):755-61.
PMID: 21784168
PMC: 3604877.
DOI: 10.1016/j.drudis.2011.07.001.
Computational method for estimating DNA copy numbers in normal samples, cancer cell lines, and solid tumors using array comparative genomic hybridization.
Abkevich V, Iliev D, Timms K, Tran T, Skolnick M, Lanchbury J
J Biomed Biotechnol. 2010; 2010.
PMID: 20706610
PMC: 2914423.
DOI: 10.1155/2010/386870.
In-depth transcriptome analysis reveals novel TARs and prevalent antisense transcription in human cell lines.
Klevebring D, Bjursell M, Emanuelsson O, Lundeberg J
PLoS One. 2010; 5(3):e9762.
PMID: 20360838
PMC: 2845605.
DOI: 10.1371/journal.pone.0009762.
Protein-based tumor molecular imaging probes.
Lin X, Xie J, Chen X
Amino Acids. 2010; 41(5):1013-36.
PMID: 20232092
PMC: 3617487.
DOI: 10.1007/s00726-010-0545-z.
Association of v-ErbA with Smad4 disrupts TGF-beta signaling.
Erickson R, Liu X
Mol Biol Cell. 2009; 20(5):1509-19.
PMID: 19144825
PMC: 2649266.
DOI: 10.1091/mbc.e08-08-0836.
ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling.
Li X, Huang Y, Jiang J, Frank S
Cell Signal. 2008; 20(11):2145-55.
PMID: 18762250
PMC: 2613789.
DOI: 10.1016/j.cellsig.2008.08.006.
Mechanistic aspects of crosstalk between GH and PRL and ErbB receptor family signaling.
Frank S
J Mammary Gland Biol Neoplasia. 2008; 13(1):119-29.
PMID: 18236142
DOI: 10.1007/s10911-008-9065-9.
Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model.
Vallera D, Stish B, Shu Y, Chen H, Saluja A, Buchsbaum D
Gut. 2008; 57(5):634-41.
PMID: 18222985
PMC: 2756191.
DOI: 10.1136/gut.2007.137802.